Cargando…

Clinical Outcomes of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 Breast Cancer Patients: A Single-Center Retrospective Study

(1) Background: Neoadjuvant therapy is widely used to treat locally advanced breast cancer. It has been recently shown that it can also improve the prognosis of patients during the early stages of breast cancer. In the past, advanced breast cancer with positive Human Epidermal growth factor Receptor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hung, Chih-Chiang, Tsai, I-Chen, Hsu, Chiann-Yi, Lin, Hsin-Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8911223/ https://www.ncbi.nlm.nih.gov/pubmed/35268525 http://dx.doi.org/10.3390/jcm11051434

Ejemplares similares

The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan
por: Hung, Chih-Chiang, et al.
Publicado: (2020)

Comparison of overall survival after neoadjuvant and adjuvant chemotherapy in patients with early breast cancer with immediate breast reconstruction after mastectomy: A retrospective, matched case-control study
por: Liu, Chia-Hua, et al.
Publicado: (2022)

The Add-On Effect of Fluorouracil, Epirubicin, and Cyclophosphamide Regimens for Neoadjuvant Chemotherapy in Human Epidermal Receptor 2 (HER2)-Positive Breast Cancer: A Single-Center Retrospective Study
por: Yoshino, Ryusei, et al.
Publicado: (2023)

Litchi seed extract inhibits epidermal growth factor receptor signaling and growth of Two Non-small cell lung carcinoma cells
por: Chung, Yuan-Chiang, et al.
Publicado: (2017)

Chemotherapy for Metastatic Gastric Cancer: Does Age Matter? A Single-Center, Retrospective, Real-World Study
por: Liao, Po-Wei, et al.
Publicado: (2022)

Neoadjuvant human epidermal growth factor receptor-2 targeted therapy in patients with locally advanced breast cancer
por: Cho, Dong Hui, et al.
Publicado: (2013)

Surgical options of the breast and clinical outcomes of breast cancer patients after neoadjuvant chemotherapy: A single-center retrospective study
por: Sang, Yuting, et al.
Publicado: (2022)

ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation
por: Shen, Chia-Hsing, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity
por: Zhang, Jiaqiang, et al.
Publicado: (2021)

Loss of human epidermal receptor-2 in human epidermal receptor-2+ breast cancer after neoadjuvant treatment: A case report
por: Yu, Jing, et al.
Publicado: (2022)

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study
por: Ozaki, Yukinori, et al.
Publicado: (2022)

Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery: A Retrospective Analysis
por: Zhang, Shichao, et al.
Publicado: (2023)

FTY720 in resistant human epidermal growth factor receptor 2-positive breast cancer
por: Chung, Wei-Pang, et al.
Publicado: (2022)

Epidermal Growth Factor Receptors and Breast Cancer
por: Farndon, J. R., et al.
Publicado: (1989)

Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status
por: Hsu, Chia-Hung, et al.
Publicado: (2016)

To treat or not to treat: a clinical series of retinal arterial macroaneurysms: A single-center retrospective study
por: Cho, Wan-Hua, et al.
Publicado: (2020)

Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study
por: Doval, Dinesh Chandra, et al.
Publicado: (2013)

Treatment Effectiveness and Tolerability of Long-term Adjuvant First- and Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor at Different Doses in Patients With Stage IIA–IIIB Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: A Retrospective Study
por: Ye, Jing-Ren, et al.
Publicado: (2022)

Prognostic Impact of Low-Level p53 Expression on Brain Astrocytomas Immunopositive for Epidermal Growth Factor Receptor
por: Tsai, Hung-Pei, et al.
Publicado: (2022)

Demoralization and Its Association with Quality of Life, Sleep Quality, Spiritual Interests, and Suicide Risk in Breast Cancer Inpatients: A Cross-Sectional Study
por: Chang, Ting-Gang, et al.
Publicado: (2022)

Epidermal growth factor receptor tyrosine kinase inhibitors for de novo T790M mutation: A retrospective study of 44 patients
por: Chang, John Wen‐Cheng, et al.
Publicado: (2022)

The epidermal growth factor receptor family in breast cancer
por: Koutras, Angelos K, et al.
Publicado: (2008)

Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer
por: Alves, Fátima R, et al.
Publicado: (2022)

Epidermal Growth Factor Receptor Mutations in Lung Adenocarcinomas: A Single Center Study from Iran
por: Basi, Ali, et al.
Publicado: (2018)

Targeting human epidermal growth factor receptor 2 enhances radiosensitivity and reduces the metastatic potential of Lewis lung carcinoma cells
por: Tien, Yun, et al.
Publicado: (2020)

Evaluation of hormone receptor, human epidermal growth factor receptor-2 and Ki-67 with core needle biopsy and neoadjuvant chemotherapy effects in breast cancer patients
por: Ge, Wen-kai, et al.
Publicado: (2015)

Clinicopathological response to neoadjuvant therapies and pathological complete response as a biomarker of survival in human epidermal growth factor receptor-2 enriched breast cancer – A retrospective cohort study
por: Davey, Matthew G., et al.
Publicado: (2021)

PIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis
por: Seo, Youjeong, et al.
Publicado: (2018)

Neoadjuvant chemotherapy with biosimilar trastuzumab in human epidermal growth factor receptor 2 overexpressed non-metastatic breast cancer: patterns of use and clinical outcomes in India
por: Joel, Anjana, et al.
Publicado: (2021)

Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
por: Huober, Jens, et al.
Publicado: (2022)

Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials
por: Nahleh, Zeina, et al.
Publicado: (2019)

Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab
por: Ha, Joo Young, et al.
Publicado: (2021)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

Human epidermal growth factor receptor-2 expression in locally advanced rectal cancer: Association with response to neoadjuvant therapy and prognosis
por: Meng, Xiangjiao, et al.
Publicado: (2014)

Epidermal growth factor receptor regulates β-catenin location, stability, and transcriptional activity in oral cancer
por: Lee, Chien-Hsing, et al.
Publicado: (2010)

Epidermal growth factor receptor mutation enhances expression of vascular endothelial growth factor in lung cancer
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Epidermal Growth Factor Receptor Mutation Enhances Expression of Cadherin-5 in Lung Cancer Cells
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
por: Hurvitz, Sara A., et al.
Publicado: (2019)

Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells
por: Watt, Heather L, et al.
Publicado: (2006)

The association between infection incidence and autoimmune diseases in breast cancer patients after anti-cancer treatment
por: Chen, Chien-Chih, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o7sqil0rfh2ba4a8slchmn3us8